» Articles » PMID: 33616712

Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23

Overview
Specialty Pathology
Date 2021 Feb 22
PMID 33616712
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Osteocyte produced fibroblast growth factor 23 (FGF23) is the key regulator of serum phosphate (Pi) homeostasis. The interplay between parathyroid hormone (PTH), FGF23 and other proteins that regulate FGF23 production and serum Pi levels is complex and incompletely characterised. Evidence suggests that the protein product of the SOST gene, sclerostin (SCL), also a PTH target and also produced by osteocytes, plays a role in FGF23 expression, however the mechanism for this effect is unclear. Part of the problem of understanding the interplay of these mediators is the complex multi-organ system that achieves Pi homeostasis in vivo. In the current study, we sought to address this using a cell line model of the osteocyte, IDG-SW3, known to express FGF23 at both the mRNA and protein levels. In cultures of differentiated IDG-SW3 cells, both PTH and recombinant human (rh) SCL remarkably induced Fgf23 mRNA expression dose-dependently within 3 h. Both rhPTH and rhSCL also strongly induced C-terminal FGF23 protein secretion. Secreted intact FGF23 levels remained unchanged, consistent with constitutive post-translational cleavage of FGF23 in this cell model. Both rhPTH and rhSCL treatments significantly suppressed mRNA levels of Phex, Dmp1 and Enpp1 mRNA, encoding putative negative regulators of FGF23 levels, and induced Galnt3 mRNA expression, encoding N-acetylgalactosaminyl-transferase 3 (GalNAc-T3), which protects FGF23 from furin-like proprotein convertase-mediated cleavage. The effect of both rhPTH and rhSCL was antagonised by pre-treatment with the NF-κβ signalling inhibitors, BAY11 and TPCK. RhSCL also stimulated FGF23 mRNA expression in ex vivo cultures of human bone. These findings provide evidence for the direct regulation of FGF23 expression by sclerostin. Locally expressed sclerostin via the induction of FGF23 in osteocytes thus has the potential to contribute to the regulation of Pi homeostasis.

Citing Articles

Evaluation of Bone Biomarkers in Renal Osteodystrophy.

Pichone A, Gomes C, Moreira C, Farias M, Leite Jr M Life (Basel). 2025; 14(12.

PMID: 39768249 PMC: 11679507. DOI: 10.3390/life14121540.


The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies.

Afsar B, Afsar R, Caliskan Y, Lentine K Calcif Tissue Int. 2024; 115(4):339-361.

PMID: 39078512 PMC: 11405501. DOI: 10.1007/s00223-024-01261-w.


Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives.

Xiaohui T, Wang L, Yang X, Jiang H, Zhang N, Zhang H J Orthop Translat. 2024; 47:39-49.

PMID: 39007037 PMC: 11245887. DOI: 10.1016/j.jot.2024.05.004.


Both enantiomers of β-aminoisobutyric acid BAIBA regulate Fgf23 via MRGPRD receptor by activating distinct signaling pathways in osteocytes.

Sakamoto E, Kitase Y, Fitt A, Zhu Z, Awad K, Brotto M Cell Rep. 2024; 43(7):114397.

PMID: 38935499 PMC: 11350516. DOI: 10.1016/j.celrep.2024.114397.


.

Gonzalez-Casaus M Adv Lab Med. 2024; 5(1):35-45.

PMID: 38634083 PMC: 11019877. DOI: 10.1515/almed-2023-0101.


References
1.
Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S . Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001; 98(11):6500-5. PMC: 33497. DOI: 10.1073/pnas.101545198. View

2.
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K . Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444(7120):770-4. DOI: 10.1038/nature05315. View

3.
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt K . Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281(10):6120-3. PMC: 2637204. DOI: 10.1074/jbc.C500457200. View

4.
Perwad F, Azam N, Zhang M, Yamashita T, Tenenhouse H, Portale A . Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005; 146(12):5358-64. DOI: 10.1210/en.2005-0777. View

5.
Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S . Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2004; 280(4):2543-9. DOI: 10.1074/jbc.M408903200. View